Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 207-856-6 | CAS number: 498-15-7
Negative control (PBS+): mean OD = 0.821
Positive control (5% SDS): % viability (MTT assay) = 18.7 ± 3.0
Test item: % viability (MTT assay) = 29.8 ± 1.3
Table 1: MTT conversion assay in living epidermis
Mean Viability %
A GLP study conducted in vitro with human epidermis model EPISKIN was performed to assess the irritancy potential of delta-3-carene (method similar to ECVAM protocol version 1.8 of February 2009). 10 µL of the test item was applied directly on epidermis for 15 min on 3 epidermis. Positive control was 10 µL of 5% (w/v) SDS solution and negative control was 10 µL of PBS (each tested on 3 epidermis). MTT conversion assay was peformed to evaluate the percentage of cellular viability of the epidermis. Positive control had a percentage of cell viability of 18.7± 3.0 and test item 29.8 ± 1.3. As the percentage of cell viability is ≤ 50 %, the test item is considered to be irritating for skin. Therefore, delta-3-carene is classified as irritating to skin, R38, according to Directive 67/548/EEC and in category 2 according to CLP Regulation (EC) N° 1272 /2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again